12 | MD Anderson Cancer Center

Targeting menin induces responses in acute leukemias with KMT2A rearrangements or NPM1 mutations

March 15, 2023

Researchers from?�鶹ӳ�� MD Anderson Cancer Center?showed that inhibiting menin with revumenib, previously known as SNDX-5613, yielded encouraging responses for advanced acute leukemias with KMT2A rearrangements or mutant?NPM1. Findings from the Phase I AUGMENT-101 trial were published today in Nature.

The overall response rate among 60 patients was 53%, and the rate of complete remission or complete...

Study discovers triple immunotherapy combination as possible treatment for pancreatic cancer

BY Julie Nagy

December 30, 2022

Researchers at �鶹ӳ�� MD Anderson Cancer Center have discovered a novel immunotherapy combination, targeting checkpoints...

Sotorasib shows clinically meaningful activity in KRAS G12C-mutated advanced pancreatic cancer

BY Aubrey Bloom

December 21, 2022

In the Phase I/II CodeBreaK 100 trial, the KRAS G12C inhibitor sotorasib achieved meaningful anticancer activity with an acceptable safety...

MD Anderson Research Highlights for December 19, 2022

December 19, 2022

�鶹ӳ�� MD Anderson Cancer Center��s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD?Anderson experts. Current advances include a cell cycle checkpoint inhibitor with potential therapeutic effects in an ovarian cancer subtype, a telementoring program for French-speaking oncology providers in Africa, insights into the relationship between obesity and immunotherapy...